Nuvation Bio Inc - Class A
Research Nuvation Bio Inc - Class A (NUVB) on Bullrun: market cap USD 2.48B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerNUVB
- ExchangeNYSE
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 2.48B
- Financial periodQ2 2026
- RevenueUSD 31.69M
- Net income-USD 62.84M
- Free cash flow-USD 43.22M
- Gross margin70.1%
Valuation Snapshot
latest market cap is USD 2.48B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 62.90M | -USD 204.63M | -USD 181.78M | 85.2% | -0.6 | USD 164.09M | USD 52.93M | USD 305.72M |
| FY2024 | USD 7.87M | -USD 567.94M | -USD 130.58M | 10.1% | -2.11 | USD 35.72M | USD 6.28M | USD 463.79M |
| FY2023 | USD 0 | -USD 75.80M | n/a | n/a | -0.35 | USD 42.65M | USD 0 | USD 605.12M |
| FY2022 | n/a | -USD 104.20M | n/a | n/a | -0.48 | USD 101.10M | USD 4.69M | USD 655.08M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 2.48B | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 3.10B | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 898.65M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 330.61M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 419.31M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 1.85B | n/a | n/a | n/a |
About Nuvation Bio Inc - Class A
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma with safusidenib against placebo.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Nuvation Bio Inc - Class A's market cap?
Nuvation Bio Inc - Class A's market capitalization is USD 2.48B.
What does Nuvation Bio Inc - Class A do?
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma with safusidenib against placebo. The company was founded in 2018 and is headquartered in New York, New York.